OncoMark

Dublin, Ireland Founded: 2011 • Age: 15 yrs Acquired By Cepheid
Tissue-based cancer diagnostics are developed by OncoMark.
Request Access

About OncoMark

OncoMark is a company based in Dublin (Ireland) founded in 2011 was acquired by Cepheid in December 2021.. OncoMark has raised $6.72 million across 5 funding rounds from investors including Cepheid, European Commission and Enterprise Ireland. OncoMark operates in a competitive market with competitors including DermTech, NeuMoDx, Biomeme, Molbio Diagnostics and OncoStem, among others.

  • Headquarter Dublin, Ireland
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $6.72 M (USD)

    in 5 rounds

  • Latest Funding Round
    $4.5 M (USD), Series A

    Jul 19, 2019

  • Investors
    Cepheid

    & 6 more

  • Employee Count
    Employee Count
  • Acquired by
    Cepheid

    (Dec 16, 2021)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of OncoMark

OncoMark has successfully raised a total of $6.72M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $4.5 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round Series A — $4.5M
  • First Round

    (01 Dec 2014)

  • Investors Count 6
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2019 Amount Series A - OncoMark Valuation Irrus Investments , Halo Business Angel Network
Feb, 2017 Amount Seed - OncoMark Valuation

investors

Feb, 2016 Amount Grant - OncoMark Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in OncoMark

OncoMark has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Cepheid, European Commission and Enterprise Ireland. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
A platform connecting angel investors to startups in Ireland.
Founded Year Domain Location
VC firm investing in the UK and the US
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by OncoMark

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - OncoMark

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Oncomark Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of OncoMark

OncoMark operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as DermTech, NeuMoDx, Biomeme, Molbio Diagnostics and OncoStem, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Adhesive patch biopsies for skin cancer detection are provided.
domain founded_year HQ Location
Developer of a platform for low cost molecular testing
domain founded_year HQ Location
Smartphone-based DNA detection platform is developed for diagnostics.
domain founded_year HQ Location
Point-of-care molecular platforms for infectious disease detection are developed.
domain founded_year HQ Location
Prognostic tests for cancer detection and recurrence risk are developed.
domain founded_year HQ Location
Point-of-care molecular diagnostics are enabled by Ultrafast Photonic PCR technology.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Oncomark

Frequently Asked Questions about OncoMark

When was OncoMark founded?

OncoMark was founded in 2011 and raised its 1st funding round 3 years after it was founded.

Where is OncoMark located?

OncoMark is headquartered in Dublin, Ireland.

Is OncoMark a funded company?

OncoMark is a funded company, having raised a total of $6.72M across 5 funding rounds to date. The company's 1st funding round was a Grant of $3M, raised on Dec 01, 2014.

What does OncoMark do?

OncoMark was founded in 2011 and is based in Dublin, Ireland. Tissue-based diagnostics for cancer are developed by the company within the biotechnology sector. The flagship OncoMasTR qPCR assay is utilized to assess recurrence risk in early-stage breast cancer patients through gene analysis. Additional products for melanoma, colorectal cancer, and prostate cancer are under development. Operations focus on prognostic tools for oncology applications.

Who are the top competitors of OncoMark?

OncoMark's top competitors include DermTech, Molbio Diagnostics and NeuMoDx.

Who are OncoMark's investors?

OncoMark has 7 investors. Key investors include Cepheid, European Commission, Enterprise Ireland, European Union, and Irrus Investments.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available